A World Without Infectious Disease

Jeffrey S. Hatfield photoJeffrey S. Hatfield


Jeffrey S. Hatfield has served as a as a member of our board of directors since December 2020. Mr. Hatfield currently serves as Chief Executive Officer at Vividion Therapeutics, Inc., a private biopharmaceutical platform company focused on discovering and developing medicines for high value ‘undruggable’ oncology and immunology targets. Mr. Hatfield has previously served as a chief executive officer in multiple other biotech companies, including Vitae Pharmaceuticals where he worked from start-up until the company’s acquisition in 2016. At Vitae, Mr. Hatfield successfully transitioned the company from a novel discovery technology to a thriving clinical-stage company with a robust pipeline of first-in-class programs generated from the company’s internal discovery engine. Mr. Hatfield took the company public in 2014, and in October 2016, Vitae was acquired by Allergan plc in an unsolicited bid. Prior to Vitae, Mr. Hatfield worked at Bristol Myers Squibb in a number of executive positions, including: Senior Vice President, Immunology and Virology Divisions; President and General Manager, BMS-Canada; and Vice President, U.S. Managed Health Care. Mr. Hatfield currently serves as chairman of the board of miRagen Therapeutics, Inc. and as a board member at aTyr Pharma. He also serves as a Key Advisory Board member for the Harvard Business School’s Blavatnik Fellowship in Life Science Entrepreneurship, and is a faculty member at Purdue University, where he teaches entrepreneurship to doctoral students. Mr. Hatfield holds an MBA from The Wharton School, University of Pennsylvania, and a B.S. from the Purdue University College of Pharmacy.